3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Investing Snacks2d
Vertex Pharma Gets Upgrade as Analysts Boost Price Target
Vertex Pharmaceuticals received an upgrade from StockNews.com, moving from a “hold” to a “buy” rating. Other analysts have ...
Zacks Investment Research on MSN2d
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
In the latest market close, Vertex Pharmaceuticals (VRTX) reached $502.92, with a +1.51% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of ...
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's second consecutive day of gains.
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Rating Increased to Buy at StockNews.com
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...
Zacks Investment Research on MSN3d
Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $495.29, marking a +1.42% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.49%.
Why Vertex Pharmaceuticals Incorporated (VRTX) is the Best Pharma Stock to Buy According to Hedge Funds
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio?
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...
Investing Snacks4d
Vertex’s Next Decade: Bigger, Bolder, and Beyond CF
Vertex Pharmaceuticals has dominated the cystic fibrosis (CF) market and is now expanding into new, high-growth areas. The ...
GEN - Genetic Engineering and Biotechnology News5d
RoslinCT and Ayrmid Pharma Intend to Partner to Manufacture FDA-Approved Cell Therapy Omisirge
The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA-OK'd and launched in 2023.